Cosmos Health Strengthens AI Drug Discovery Platform with Appointment of Athos Therapeutics CEO Dr. Dimitrios Iliopoulos
Key Insights
Cosmos Health Inc. (search) (NASDAQ:COSM) has appointed Dr. Dimitrios Iliopoulos, Co-Founder and CEO of Athos Therapeutics, to its Advisory Board to support AI-driven drug discovery initiatives.
Dr. Iliopoulos brings expertise from developing AthosOmics.AI platform, which discovered ATH-063, an AI-derived small molecule currently in Phase 2 trials for ulcerative colitis (search).
The appointment strengthens Cosmos Health's biotechnology platform as the company expands R&D initiatives in oncology, autoimmune diseases (search), and other therapeutic areas.
Cosmos Health Inc. (search) (NASDAQ:COSM) announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, bringing world-renowned expertise in artificial intelligence-driven drug discovery and clinical-stage therapeutic development to the diversified healthcare group. The appointment positions Cosmos Health to accelerate its biotechnology initiatives through advanced AI capabilities.
AI Platform Expertise and Clinical Success
Dr. Iliopoulos currently serves as Co-Founder and CEO of Athos Therapeutics Inc. (search), an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmune diseases (search). Under his leadership, Athos has developed AthosOmics.AI, a proprietary AI-driven drug development platform that resulted in the discovery of ATH-063, an AI-derived small molecule currently being evaluated in a Phase 2 clinical trial in ulcerative colitis (search) patients.
His academic career spans prestigious institutions, beginning as an Assistant Professor of Microbiology & Immunology at Harvard Medical School before becoming a tenured Associate Professor of Medicine at the UCLA School of Medicine (search). At UCLA, he founded and directed the UCLA Center for Systems Biomedicine, funded by the Eli & Edythe Broad Foundation.
Scientific Impact and Recognition
Dr. Iliopoulos has received multiple national and international awards from institutions including the National Institutes of Health (NIH), the American Association for Cancer (search) Research, the Sidney Kimmel Foundation, and the Leona & Harry Helmsley Foundation for identifying novel genes and advancing drug development for autoimmune diseases (search) and cancer. His research productivity includes more than 130 peer-reviewed scientific articles in leading biomedical journals, with over 24,000 citations, earning recognition in Stanford University's list of the top 2% of scientists worldwide.
His innovative AI-enabled strategies have significantly accelerated drug discovery in oncology and autoimmune diseases (search). Notable achievements include pioneering work at Harvard in drug repositioning that demonstrated metformin, a widely used anti-diabetic drug, possesses anti-cancer (search) properties, leading to multiple cancer clinical trials. At UCLA, his team identified miR-124 (search) as a key anti-inflammatory drug target for ulcerative colitis (search), contributing to subsequent clinical development programs in inflammatory bowel disease (search).
Strategic Vision for Cosmos Health
"I am truly honored to join Cosmos Health's Advisory Board and to work alongside Greg Siokas, whose visionary leadership and relentless focus on long-term value creation have positioned Cosmos Health as a differentiated and innovation-driven healthcare platform," Dr. Iliopoulos commented. "His ability to combine disciplined execution with bold strategic vision is rare. I look forward to supporting the Company's biotechnology and AI-driven drug development efforts as it continues to expand its scientific capabilities and build meaningful clinical and commercial impact."
Greg Siokas, CEO of Cosmos Health, stated: "We are proud to welcome Dr. Iliopoulos to our Advisory Board. His deep expertise in AI-driven drug discovery, translational medicine, and clinical development significantly strengthens our biotechnology platform. As we continue to expand our R&D initiatives and evaluate opportunities in oncology, autoimmune diseases (search), and other high-value therapeutic areas, his experience at the intersection of science, clinical execution, and biotech strategy will be instrumental in shaping our long-term direction."
Business and Financial Expertise
Beyond his scientific credentials, Dr. Iliopoulos holds an MBA and finance certification from UCLA Anderson School of Management and Stanford Graduate School of Business. He co-authored "Biotechnology Valuation & Investing (2nd Edition)" and developed a real-options financial framework for valuing early-stage biotechnology products and companies, bringing valuable business acumen to Cosmos Health's strategic initiatives.
Cosmos Health Inc. (search), incorporated in 2009 in Nevada, operates as a diversified, vertically integrated global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands. The company has established R&D partnerships targeting major health disorders such as obesity (search), diabetes (search), and cancer (search), enhanced by artificial intelligence drug repurposing technologies.